Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 clinical trial of ORP-101

Trial Profile

A phase 2 clinical trial of ORP-101

Phase of Trial: Phase II

Latest Information Update: 30 Apr 2018

At a glance

  • Drugs ORP 101 (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Apr 2018 New trial record
    • 25 Apr 2018 According to an OrphoMed media release, in May 2017, OrphoMed completed a $39 million Series A financing with New Enterprise Associates, Takeda Ventures, Pappas Capital and Relativity Healthcare. This capital will be used to advance the clinical development of ORP-101 through Phase 2.
    • 25 Apr 2018 According to an OrphoMed media release, the goal of the company is to advance ORP-101 into Phase 2 by the end of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top